A Novel CA4P Polymeric Nanoparticle for Murine Hepatoma Therapy

Zhi-Lin Liu; Xi-Tong Ren; Yue Huang; Jia-Li Sun; Xiao-Shuang Wang; Meng-Fei Zheng; Lin-Jie Cui; Xue-Fei Zhang; Zhao-Hui Tang

doi:10.1007/s10118-023-2921-7

Your Location：

Home >

Browse articles >

A Novel CA4P Polymeric Nanoparticle for Murine Hepatoma Therapy

RESEARCH ARTICLE | Updated：2023-07-18

- A Novel CA4P Polymeric Nanoparticle for Murine Hepatoma Therapy
- A Novel CA4P Polymeric Nanoparticle for Murine Hepatoma Therapy
- 高分子科学（英文版） 2023年41卷第8期页码：1223-1229
- Affiliations：
  
  a.Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
  b.Jilin Biomedical Polymers Engineering Laboratory, Changchun 130022, China
  c.School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei 230026, China
  d.No. 1 Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun 130033, China
  e.Key Laboratory of Environmentally Friendly Chemistry and Applications of Ministry of Education and Key Laboratory of Polymeric Materials & Application Technology of Hunan Province, College of Chemistry, Xiangtan University, Xiangtan 411105, China
- Author bio：
  
  zxf7515@xtu.edu.cn (X.F.Z.)
  ztang@ciac.ac.cn (Z.H.T.)
- Funds：
  
  This work was financially supported by the Ministry of Science and Technology of China (No. 2022YFE0110200), the Natural Science Foundation of Hunan Province of China (No. 2021JJ30680) and the National Natural Science Foundation of China (Nos. 52203198, 52025035 and 52103195).;Electronic supplementary information (ESI) is available free of charge in the online version of this article at http://doi.org/10.1007/s10118-023-2921-7.
- DOI：10.1007/s10118-023-2921-7
  中图分类号：
- 收稿：2022-11-19，
  
  修回：2022-12-6，
  
  录用：2022-12-6，
  
  网络首发：2023-02-10，
  
  纸质出版：2023-08-01
- Accepted：
Scan QR Code
Liu, Z. L.; Ren, X. T.; Huang, Y.; Sun, J. L.; Wang, X. S.; Zheng, M. F.; Cui, L. J.; Zhang, X. F.; Tang, Z. H. A novel CA4P polymeric nanoparticle for murine hepatoma therapy. Chinese J. Polym. Sci. 2023, 41, 1223–1229

Zhi-Lin Liu, Xi-Tong Ren, Yue Huang, et al. A Novel CA4P Polymeric Nanoparticle for Murine Hepatoma Therapy[J]. Chinese Journal of Polymer Science, 2023, 41(8): 1223-1229.
Liu, Z. L.; Ren, X. T.; Huang, Y.; Sun, J. L.; Wang, X. S.; Zheng, M. F.; Cui, L. J.; Zhang, X. F.; Tang, Z. H. A novel CA4P polymeric nanoparticle for murine hepatoma therapy. Chinese J. Polym. Sci. 2023, 41, 1223–1229 DOI： 10.1007/s10118-023-2921-7.

Zhi-Lin Liu, Xi-Tong Ren, Yue Huang, et al. A Novel CA4P Polymeric Nanoparticle for Murine Hepatoma Therapy[J]. Chinese Journal of Polymer Science, 2023, 41(8): 1223-1229. DOI： 10.1007/s10118-023-2921-7.

摘要

Abstract

Combretastatin A4 phosphate (CA4P) is a potent vascular disrupting agent with good water solubility. However

it is only effective at high doses

which decreases clinical applicability. Herein

we designed stable CA4P polymeric nanoparticles (CA4P NPs) consisting of various cholesterol derivatives

and with a drug loading efficacy of 93%. The nanoparticles released CA4P in a sustained manner and achieved a 72% inhibition rate in the murine H22 liver tumor model

which was about 2.9-fold higher than that of free CA4P (24.6%). Furthermore

the carrier components of CA4P NPs were metabolized to arginine

cholesterol

ethanol and poly(ethylene glycol)

in vivo

; therefore

the CA4P NPs are safe and have significant potential for clinical translation.

关键词

Keywords

references

Askoxylakis,V.;Arvanitis,C.D.;Wong,C.S.F.;Ferraro,G.B.;Jain,R.K.Emergingstrategiesfordeliveringantiangiogenictherapiestoprimaryandmetastaticbraintumors. Adv. Drug Deliv. Rev. 2017 , 119 ,159−174..

Li,Z.;Di,C.;Li,S.;Yang,X.;Nie,G.Smartnanotherapeutictargetingoftumorvasculature. Acc. Chem. Res. 2019 , 52 ,2703−2712..

Yamakawa,D.;Kidoya,H.;Sakimoto,S.;Jia,W.;Takakura,N.2-MethoxycinnamaldehydeinhibitstumorangiogenesisbysuppressingTie2activation. Biochem. Biophys. Res. Commun. 2011 , 415 ,174−80..

Hong,S.;Zheng,D.W.;Zhang,C.;Huang,Q.X.;Cheng,S.X.;Zhang,X.Z.Vasculardisruptingagentinducedaggregationofgoldnanoparticlesforphotothermallyenhancedtumorvasculardisruption. Sci. Adv. 2020 , 6 ,eabb0020..

Smolarczyk,R.;Czapla,J.;Jarosz-Biej,M.;Czerwinski,K.;Cichon,T.Vasculardisruptingagentsincancertherapy. Eur. J. Pharmacol. 2021 , 891 ,173692..

DaeiFarshchiAdli,A.;Jahanban-Esfahlan,R.;Seidi,K.;Samandari-Rad,S.;Zarghami,N.AnoverviewonVadimezan(DMXAA):thevasculardisruptingagent. Chem. Biol. Drug Design 2018 , 91 ,996−1006..

Liu,Z.;Yu,H.;Shen,N.;Tang,Z.;Chen,X.AROS-stimulus-responsivenanocarrierloadingwithguanidine-modifiedhydroxycamptothecinprodrugforenhancedanti-tumorefficacy. CCS Chem. 2020 , 2 ,305−316..

Liu,Z.L.;Ma,S.;Sun,J.L.;Si,X.H.;Tang,Z.H.;Chen,X.S.Reactiveoxygenspeciesresponsivecore-shellnanoparticlesincreasetumorenrichmentandendocytosis. Acta Polymerica Sinica (inChinese) 2020 , 51 ,1153−1159..

Liu,Z.;Tang,Z.;Zhang,D.;Wu,J.;Si,X.;Shen,N.;Chen,X.AnovelGSHresponsivepoly(alpha-lipoicacid)nanocarrierbondingwiththehonokiol-DMXAAconjugateforcombinationtherapy. Sci. China Mater. 2019 , 63 ,307−315..

Dong,S.;Ma,S.;Liu,Z.L.;Ma,L.L.;Zhang,Y.;Tang,Z.H.;Deng,M.X.;Song,W.T.Functionalamphiphilicpoly(2-oxazoline)blockcopolymersasdrugcarriers:therelationshipbetweenstructureanddrugloadingcapacity. Chinese J. Polym. Sci. 2021 , 39 ,865−873..

Wang,T.;Wu,C.;Wang,C.;Zhang,G.;Arnst,K.E.;Yao,Y.;Zhang,Z.;Wang,Y.;Pu,D.;Li,W.UnravelingthemolecularmechanismofBNC105,aphaseIIclinicaltrialvasculardisruptingagent,providesinsightsintodrugdesign. Biochem. Biophys. Res. Commun 2020 ..

Liu,Z.;Zhang,Y.;Shen,N.;Sun,J.;Tang,Z.;Chen,X.DestructionoftumorvasculaturebyvasculardisruptingagentsinovercomingthelimitationofEPReffect. Adv. Drug Deliv. Rev. 2022 , 183 ,114138..

Sherbet,G.V.Suppressionofangiogenesisandtumourprogressionbycombretastatinandderivatives. Cancer Lett. 2017 , 403 ,289−295..

Galbraith,S.M.;Chaplin,D.J.;Lee,F.;Stratford,M.R.L.;Locke,R.J.;Vojnovic,B.;Tozer,G.M.EffectsofcombretastatinA4phosphateonendothelialcellmorphology in vitro andrelationshiptotumourvasculartargetingactivity in vivo . Anticancer Res. 2001 , 21 ,93−102..

Hasani,A.;Leighl,N.Classificationandtoxicitiesofvasculardisruptingagents. Clinical Lung Cancer 2011 , 12 ,18−25..

Dong,M.;Liu,F.;Zhou,H.;Zhai,S.;Yan,B.NovelNaturalproduct-andprivilegedscaffold-basedtubulininhibitorstargetingthecolchicinebindingsite. Molecules 2016 , 21 ,1375..

An,Y.;Chen,C.;Zhu,J.D.;Dwivedi,P.;Zhao,Y.J.;Wang,Z.Hypoxia-inducedactivitylossofaphoto-responsivemicrotubuleinhibitorazobenzenecombretastatinA4. Front. Chem. Sci. Eng. 2020 , 14 ,880−888..

Winn,B.A.;Devkota,L.;Kuch,B.;MacDonough,M.T.;Strecker,T.E.;Wang,Y.;Shi,Z.;Gerberich,J.L.;Mondal,D.;Ramirez,A.J.;Hamel,E.;Chaplin,D.J.;Davis,P.;Mason,R.P.;Trawick,M.L.;Pinney,K.G.BioreductivelyactivatableprodrugconjugatesofcombretastatinA-1andcombretastatinA-4asanticanceragentstargetedtowardtumor-associatedhypoxia. J. Nat. Prod. 2020 , 83 ,937−954..

Welford,A.F.;Biziato,D.;Coffelt,S.B.;Nucera,S.;Fisher,M.;Pucci,F.;DiSerio,C.;Naldini,L.;DePalma,M.;Tozer,G.M.;Lewis,C.E.TIE2-expressingmacrophageslimitthetherapeuticefficacyofthevascular-disruptingagentcombretastatinA4phosphateinmice. J. Clin. Invest. 2011 , 121 ,1969−73..

Jaroch,K.;Karolak,M.;Gorski,P.;Jaroch,A.;Krajewski,A.;Ilnicka,A.;Sloderbach,A.;Stefanski,T.;Sobiak,S.Combretastatins: in vitro structure-activityrelationship,modeofactionandcurrentclinicalstatus. Pharmacol. Rep. 2016 , 68 ,1266−1275..

Liu,Y.;Wang,S.;Zhao,X.;Feng,Y.;Bormans,G.;Swinnen,J.;Oyen,R.;Huang,G.;Ni,Y.;Li,Y.Predictingclinicalefficacyofvasculardisruptingagentsinrodentmodelsofprimaryandsecondarylivercancers:anoverviewwithimaging-histopathologycorrelation. Diagnostics 2020 , 10 ,78..

Hinnen,P.;Eskens,F.A.Vasculardisruptingagentsinclinicaldevelopment. Br. J. Cancer 2007 , 96 ,1159−1165..

Gao,M.;Zhang,D.;Yao,N.;Jin,Q.;Jiang,C.;Zhang,J.;Wang,F.Enhancingintratumoralbiodistributionandantitumoractivityofnab-paclitaxelthroughcombinationwithavasculardisruptingagent,combretastatinA-4-phosphate. Cancer Chemoth. Pharmacol. 2019 , 84 ,1187−1194..

Brown,A.W.;Holmes,T.;Fisher,M.;Tozer,G.M.;Harrity,J.P.A.;Kanthou,C.Evaluationofsydnone-basedanaloguesofcombretastatinA-4phosphate(CA4P)asvasculardisruptingagentsforuseincancertherapy. Chem. Med. Chem. 2018 , 13 ,2618−2626..

Liu,T.Z.;Zhang,D.W.;Song,W.T.;Tang,Z.H.;Zhu,J.M.;Ma,Z.M.;Wang,X.D.;Chen,X.S.;Tong,T.Apoly(L-glutamicacid)-combretastatinA4conjugateforsolidtumortherapy:Markedlyimprovedtherapeuticefficiencythroughitslowtissuepenetrationinsolidtumor. Acta Biomaterialia 2017 , 53 ,179−189..

Folkman,J.Roleofangiogenesisintumorgrowthandmetastasis. Semin. Oncol. 2002 , 29 ,15−8..

Liu,Z.L.;Shen,N.;Tang,Z.H.;Zhang,D.W.;Ma,L.L.;Yang,C.G.;Chen,X.S.AneximiousandaffordableGSHstimulus-responsivepoly(alpha-lipoicacid)nanocarrierbondingcombretastatinA4fortumortherapy. Biomater. Sci-Uk. 2019 , 7 ,2803−2811..

Deng,C.;Zhao,J.;Zhou,S.;Dong,J.;Cao,J.;Gao,J.;Bai,Y.;Deng,H.ThevasculardisruptingagentCA4PimprovestheantitumorefficacyofCAR-Tcellsinpreclinicalmodelsofsolidhumantumors. Mol. Ther. 2020 , 28 ,75−88..

Thebault,C.J.;Ramniceanu,G.;Boumati,S.;Michel,A.;Seguin,J.;Larrat,B.;Mignet,N.;Menager,C.;Doan,B.T.TheranosticMRIliposomesformagnetictargetingandultrasoundtriggeredreleaseoftheantivascularCA4P. J. Control. Rel.: Official J. Control. Rel. Soc. 2020 , 322 ,137−148..

Satterlee,A.B.;Rojas,J.D.;Dayton,P.A.;Huang,L.Enhancingnanoparticleaccumulationandretentionindesmoplastictumors via vasculardisruptionforinternalradiationtherapy. Theranostics 2017 , 7 ,253−269..

浏览量

263

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

A Paradigm for BF3 Co-initiated Cationic Polymerization with Low Dispersity: Introducing Acetonitrile and Lowering the Reaction Temperature

Molecularly Engineered Polyimide Films with Switchable Cavitation for Bidirectional Passive Thermal Regulation

Enhancing Processability of Phenylethynyl-terminated Imide Oligomers and Properties of Cured Polyimides via ―CF3 Incorporation

Special Topic: Chirality in Polymers

From Molecular Defect to Macroscopic Performance: Manipulating Dichroism and Mechanics in Iodine-doped Poly(vinyl alcohol) via Ethylene Incorporation